I always figured management at formerly independent Encysive Pharmaceuticals was just incompetent in its failure to get its pulmonary arterial hypertension drug Thelin approved in the U.S. time and time and time again.
But now I'm thinking Thelin is just cursed.
The drug's new owner, Pfizer
Bye-bye, Thelin; at least Pfizer didn't pay much for you.
With every loser, there's a winner. Or in this case a few, since there are a number of pulmonary arterial hypertension drugs on the market. Pfizer sells Revatio, which is just Viagra under a different name, so Pfizer isn't completely out of the market. Similarly, Eli Lilly's
But the two drugs that will likely benefit most are Actelion's Tracleer and Gilead Sciences'
It's always a little sad to see a drug die in development, but considering the long and tumultuous road Thelin has been on, maybe it's only fitting to see it have a sudden heart attack and die before ever making it to the market in the U.S.
Interested in keeping track of Pfizer and the other drugs in its pipeline? Click here to add it to My Watchlist, which will help you keep track of all our Foolish analysis on Pfizer.
Pfizer is a Motley Fool Inside Value recommendation. Gilead Sciences is a Motley Fool Stock Advisor selection. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors.